Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.49 |
| ▸ | CD38 | P28907 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280488 | 0.84 | CD38 (0.41) | SYKCD38CYP3A4 | |
| SCHEMBL2483074 | 0.81 | CD38 (0.57) | CD38CYP3A4 | |
| SCHEMBL2694988 | 0.79 | JAK3 (0.50) | SYK | |
| SCHEMBL12280094 | 0.79 | SMN1; SMN2 (0.42) | SYKCYP3A4 | |
| SCHEMBL12280125 | 0.79 | TRPV1 (0.46) | SYK | |
| SCHEMBL12280297 | 0.79 | JAK3 (0.41) | SYKCD38 | |
| SCHEMBL2476571 | 0.78 | CD38 (0.54) | SYKCD38CYP3A4 | |
| SCHEMBL2474877 | 0.78 | CD38 (0.54) | CD38CYP3A4 | |
| SCHEMBL2694637 | 0.78 | JAK3 (0.52) | SYK | |
| SCHEMBL2342817 | 0.77 | SYK (0.42) | SYKCD38CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | SYK 492/4885CD38 1118/4885CYP3A4 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.